Development of pyrene-based fluorescent ether lipid as inhibitor of SK3 ion channels.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 22 06 2020
revised: 04 09 2020
accepted: 24 09 2020
pubmed: 14 10 2020
medline: 22 4 2021
entrez: 13 10 2020
Statut: ppublish

Résumé

We report the synthesis of three bioactive pyrene-based fluorescent analogues of Ohmline which is the most efficient and selective inhibitor of SK3 ion channel. The interaction of these Ohmline-pyrene (OP1-3) with liposomes of different composition reveals that only OP2 and OP3 are readily integrated into liposomes. Fluorescence measurements indicate that, depending on their concentration, OP2 and OP3 exist either as monomer or as a mixture of monomer and excimers within the liposome bilayer. Among the three Ohmline Pyrene compounds (OP1-3) only OP2 is able to reduce SK3 currents and is the first efficient fluorescent modulator of SK3 channel as revealed by patch clamp measurements (- 71.3 ± 13.3% at 10 μM) and by its inhibition of SK3-dependent cancer cell migration at (-32.5% ± 4.8% at 1 μM). We also report the first fluorescence study on living breast cancer cells (MDA-MB-231) showing that OP2 is rapidly integrated in bio-membranes followed by cell internalization.

Identifiants

pubmed: 33049604
pii: S0223-5234(20)30866-7
doi: 10.1016/j.ejmech.2020.112894
pii:
doi:

Substances chimiques

1-O-hexadecyl-2-O-methylglycero-3-lactose 0
Fluorescent Dyes 0
Glycolipids 0
KCNN3 protein, human 0
Potassium Channel Blockers 0
Pyrenes 0
Small-Conductance Calcium-Activated Potassium Channels 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112894

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alicia Bauduin (A)

Univ Brest, CEMCA UMR CNRS 6521, 6 Avenue Victor Le Gorgeu, F-29238, Brest, France.

Marion Papin (M)

Univ Tours, Inserm U1069 Nutrition, Croissance et Cancer (N2C), Faculté de pharmacie, 10 Boulevard Tonnellé, 37032, Tours Cedex, France.

Aurélie Chantôme (A)

Univ Tours, Inserm U1069 Nutrition, Croissance et Cancer (N2C), Faculté de pharmacie, 10 Boulevard Tonnellé, 37032, Tours Cedex, France.

Hélène Couthon (H)

Univ Brest, CEMCA UMR CNRS 6521, 6 Avenue Victor Le Gorgeu, F-29238, Brest, France.

Laure Deschamps (L)

Univ Brest, CEMCA UMR CNRS 6521, 6 Avenue Victor Le Gorgeu, F-29238, Brest, France.

Jose Requejo-Isidro (J)

Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain; Unidad de Nanobiotecnología, CNB-CSIC-IMDEA Nanociencia Associated Unit, Madrid, Spain.

Christophe Vandier (C)

Univ Tours, Inserm U1069 Nutrition, Croissance et Cancer (N2C), Faculté de pharmacie, 10 Boulevard Tonnellé, 37032, Tours Cedex, France.

Paul-Alain Jaffrès (PA)

Univ Brest, CEMCA UMR CNRS 6521, 6 Avenue Victor Le Gorgeu, F-29238, Brest, France. Electronic address: pjaffres@univ-brest.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH